Eliem Therapeutics(US:ELYM)2026-03-05 12:20Financial Performance - The company incurred a net loss of $59.9 million for the year ended December 31, 2025, compared to a net loss of $73.9 million in 2024, reflecting a decrease of $14.0 million [713]. - Total operating expenses decreased from $82.0 million in 2024 to $67.9 million in 2025, a reduction of $14.1 million [713]. - Interest income increased slightly from $8.1 million in 2024 to $8.3 million in 2025 due to higher invested balances [717]. - The company’s foreign currency loss for the year ended December 31, 2025, was not material compared to the previous year [718]. Research and Development - Research and development expenses increased from $14.3 million in 2024 to $46.7 million in 2025, primarily due to a $19.1 million increase for the budoprutug program [714]. - The company anticipates that its research and development expenses will increase substantially as it conducts ongoing clinical trials and development activities [705]. - The company anticipates increased expenses in the foreseeable future as it advances product candidates and expands corporate infrastructure [729]. Cash and Financing Activities - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $160.7 million [719]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $160.7 million, expected to fund operations into 2028 [729]. - For the year ended December 31, 2025, net cash provided by investing activities was $2.8 million, primarily from $111.1 million in proceeds from maturities of marketable securities, offset by $108.1 million in purchases of marketable securities [725]. - For the year ended December 31, 2024, net cash used by investing activities was $121.1 million, mainly due to $132.2 million in purchases of marketable securities and a $5.0 million promissory loan [726]. - For the year ended December 31, 2025, net cash used by financing activities was less than $0.1 million, with a significant exchange of 20,440,000 shares for a pre-funded warrant [727]. - For the year ended December 31, 2024, net cash provided by financing activities was $130.7 million, primarily from $119.7 million in proceeds from the issuance of common stock [728]. Future Outlook and Risks - The company expects to continue incurring operating losses for the foreseeable future and will need to raise substantial additional capital [699]. - Future funding requirements will depend on various factors, including the progress and costs of clinical trials and potential commercialization activities [730]. - The company is subject to risks related to biopharmaceutical development, which may lead to unforeseen expenses and delays [730]. Internal Controls - The company identified material weaknesses in internal controls over financial reporting, with two remaining unremediated as of December 31, 2025 [742]. Obligations - The company has obligations under the Asset Purchase Agreement with Acelyrin, contingent on achieving specified development and commercial milestones [735].